EHA 2025 | The Phase III InMIND study: tafasitamab plus lenalidomide and rituximab in R/R follicular lymphoma

Thank you so much for this question. I was given the presentation yesterday on this topic with the data on INMIND, which I believe is really a game changer in the treatment of relapsed/refractory follicular lymphoma. It is a double-blind randomized study, with more than 550 patients, who were randomized and there was a significant improvement of the primary endpoint. It was the progression-free survival with a 57% risk reduction of death, progression, or relapse. So the control arm was R-squared and the experimental arm was tafasitamab plus R-squared. Tafasitamab, an anti-CD19 antibody, rituximab, an anti-CD20 antibody, and lenalidomide, an immunomodulatory drug. And this new combination, which I have mentioned, led to a significant improvement of the progression-free survival, but it was really better in all pre-planned subsets, and there were several stratification factors: POD24, resistance refractoriness to rituximab, and the number of previous lines, and in all these subsets, it has been shown to be better. There was a shift that favors the tafasitamab arm, which favors the tafasitamab arm. So I think that this is a really important issue. There have been questions about POD24, so approximately one third of the patients were POD24 positive. When we defined POD24 since the time of diagnosis, when we defined POD24 since the time of treatment, there was more than 40% in both arms, and it was again a positive shift, which favors the tafasitamab arm. So at the end, this is a one-year treatment, no maintenance, and it really improves the outcome of the patient. So I think that because it could be easily administered, not only in academic centers, but on the community level as well, it could change the practice.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.